Is the European Pediatric Medicine Regulation working for children and adolescents with cancer?

Clinical Cancer Research

Volumn 19, Issue 6, 2013, Pages 1315-1325

  Vassal, Gilles ^a   Geoerger, Birgit ^a   Morland, Bruce ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ASPARAGINASE; BEVACIZUMAB; BOSUTINIB; BRENTUXIMAB VEDOTIN; CARBOPLATIN; CEDIRANIB; CILENGITIDE; CISPLATIN; CRIZOTINIB; CYCLOPHOSPHAMIDE; DASATINIB; DENOSUMAB; EVEROLIMUS; GENERIC DRUG; MERCAPTOPURINE; NAVITOCLAX; NELARABINE; NILOTINIB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PIXANTRONE; PLERIXAFOR; PRALATREXATE; RITUXIMAB; TEGAFUR; THIOTEPA; UNINDEXED DRUG; VELIPARIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANEMIA; ARTICLE; B CELL LYMPHOMA; BONE METASTASIS; BRAIN TUMOR; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DRUG APPROVAL; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; EUROPE; GASTROINTESTINAL STROMAL TUMOR; GLIOMA; HEALTH CARE ACCESS; HUMAN; HYPERURICEMIA; LEUKEMIA; LUNG CANCER; LYMPHOBLASTOMA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MELANOMA; MELANOMA METASTASIS; NAUSEA AND VOMITING; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; PEDIATRIC INVESTIGATION PLAN; PRIORITY JOURNAL; SOLID TUMOR; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; T CELL LYMPHOMA; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT PLANNING; TUMOR LYSIS SYNDROME;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; DRUG APPROVAL; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MARKETING; NEOPLASMS; PEDIATRICS;

EID: 84875127324     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2551     Document Type: Article

References (18)

1. Hirschfeld S, Saint-Raymond A. Pediatric regulatory initiatives. Handb Exp Pharmacol 2011;205:245-68.
2. Vassal G. Will children with cancer benefit from the new European Pediatric Medicines Regulation? Eur J Cancer 2009;45:1535-46.
3. Pritchard-Jones K, Dixon-Woods M, Naafs-Wilstra M, Valsecchi MG. Improving recruitment to clinical trials for cancer in childhood. Lancet Oncol 2008;9:392-9.
4. Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, et al. EUROCARE Working Group Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer 2009; 45:992-1005.
5. European Medicines Agency. Product specific decision on EMA website. Available from: http://www.ema.europa.eu/ema/.
6. Olski TM, Lampus SF, Gherarducci G, Saint Raymond A. Three years of pediatric regulation in the European Union. Eur J Clin Pharmacol 2011;67:245-52.
7. Cole KA, Maris JM. New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome. Clin Cancer Res 2012;18:2423-8.
8. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 2009;27:1007-13.
9. Ladenstein R, Valteau-Couanet D, Brock P, Yaniv I, Castel V, Laureys G, et al. Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. J Clin Oncol 2010;28:3516-24.
10. Kwak EL, Bang YJ, Camidge DR, ShawAT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
11. Carpenter EL, Mossé YP. Targeting ALK in neuroblastoma-preclinical and clinical advancements. Nat Rev Clin Oncol 2012;9: 391-9.
12. Mosse YP, Balis FM, Lim MS, Laliberte J, Voss SD, Fox El, et al. Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: a Children's Oncology Group phase I consortium study. J Clin Oncol 30, 2012 (suppl; abstr 9500).
13. Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, et al. editors. Cancer incidence and survival among children and adolescents: United States SEER program 1975-1995, Bethesda, MD: National Cancer Institute, SEER Program. NIH Pub. No. 99-4649; 1999.
14. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extracerebellar pilocytic astrocytoma. Acta Neuropathol 2011;121: 397-405.
15. Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010;116:1919-23.
16. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
17. Saint Raymond A, Herold R. Medicines for paediatric oncology: can we overcome the failure to deliver? Expert Rev Clin Pharmacol 2012;5:493-5.
18. Zwaan CM, Kearns P, Caron H, Verschuur A, Riccardi R, Boos J, et al. The role of the 'innovative therapies for children with cancer' (ITCC) European consortium. Cancer Treat Rev 2010;36: 328-34.